In a recent post on the IVI-sponsored Health Affairs featured blog series, Joshua Liao and Mark Pauly examine the role of government regulation of orphan drugs in rising drug prices, providing some specific examples and how they relate to the provisions of the Orphan Drug Act. Liao and Pauly also present some potential solutions to the problem, including policy and market approaches.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
